gilead sciences - Search News

Gilead Sciences, Cognizant

Gilead Sciences, Inc. (GILD): AI Partnerships Enhancing Biopharmaceutical Advancements

We recently published a list of 10 AI News and Ratings You Should Not Miss. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other AI news and ratings you should not miss.

Pharmabiz · 8h

Cognizant and Gilead expand partnership to drive greater value through advanced technology applications

Cognizant and Gilead expand partnership to drive greater value through advanced technology applications: Teaneck, New Jersey Friday, January 31, 2025, 14:00 Hrs [IST] Cognizant ha

Business Insider · 1d

Cognizant Expands Partnership With Gilead Sciences To Enhance Efficiency And AI Integration

Thursday announced that it has expanded its long-standing collaboration with Gilead Sciences (GILD) to enhance cost

Hosted on MSN · 1d

Cognizant expands AI services for Gilead Sciences

Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ: NASDAQ:GILD), aiming to enhance Gilead's customer service, employee engagement,

Contract Pharma · 1d

Cognizant Expands Partnership with Gilead

Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology applications. By deploying these solutions across the value chain, Cognizant aims to help Gilead achieve significant benefits through a newly optimized financial framework.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,201.60 today based on a ...

Gilead Worker Accused of Sex Harassment Advances Defamation Suit

Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...

10h

Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Breaking Down Gilead Sciences: 22 Analysts Share Their Views

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Gilead Sciences Inc. stock outperforms competitors despite losses on the day

The stock's fall snapped a two-day winning streak.

Business Wire2d

Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

1don MSN

Gilead Sciences' SWOT analysis: stock outlook shaped by HIV and oncology progress

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

Gilead Sciences Inc. stock outperforms competitors on strong trading day

Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Gilead Sciences, Cognizant

Related topics